Cambridge, UK, 10 April 2024 – Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted immune cell enhancing therapeutics, has presented preclinical data at the 2024 American Association for Cancer Research (AACR) Annual Meeting on its two leading programmes:.

英国剑桥，2024年4月10日–Crescendo Biologics Ltd（Crescendo）是一家开发新型靶向免疫细胞增强疗法的临床阶段免疫肿瘤学公司，已在2024年美国癌症研究协会（AACR）年会上介绍了其两个领先项目的临床前数据：。

Clinical programme CB307 a ‘1st and only’ in class CD137 (4-1BB) x PSMA bispecific for end-stage prostate cancer patients

临床计划CB307是终末期前列腺癌患者CD137（4-1BB）x PSMA双特异性的“第一且唯一”类

First ‘2 in 1’ immune cell engager CB699, a mesothelin (MSLN) directed molecule designed to target both CD40 and CD137

第一个“二合一”免疫细胞参与者CB699，一种间皮素（MSLN）定向分子，设计用于靶向CD40和CD137

These programmes are derived from Crescendo’s proprietary Humabody® VH platform which is associated with superior tumour penetration compared to traditional antibodies.

这些程序源自Crescendo专有的Humabody®VH平台，与传统抗体相比，该平台具有优越的肿瘤穿透性。

Theodora Harold, CEO at Crescendo Biologics, commented: “Crescendo employs a tumour-targeted approach to directing immune cell activation against cancer. The data from our two lead programmes highlight the potential of immuno-oncology therapies that are potent and long-lasting, yet well-tolerated by patients..

Crescendo Biologics首席执行官西奥多·哈罗德（TheodoraHarold）评论道：“Crescendo采用了一种针对肿瘤的方法来指导针对癌症的免疫细胞激活。我们两个主要项目的数据突显了免疫肿瘤学疗法的潜力，这些疗法有效且持久，但患者耐受性良好。。

“The pharmacology data we have shared on CB307, underpins its clinical development in PSMA+ metastatic castration-resistant prostate cancer (mCRPC), which continues at pace in our ongoing Phase 1b trial. CB699 is a pipeline programme which has excited us with its potential and I am delighted that we have been able to share our early research at this year’s conference.

“我们在CB307上共享的药理学数据支持了其在PSMA+转移性去势抵抗性前列腺癌（mCRPC）中的临床开发，该临床开发在我们正在进行的1b期试验中仍在继续。CB699是一个管道计划，它的潜力使我们兴奋不已，我很高兴我们能够在今年的会议上分享我们的早期研究。

These preclinical findings support this candidate’s progression into clinical development, and we look forward to providing further insights as the programme matures.”.

这些临床前研究结果支持该候选人进入临床开发阶段，我们期待着随着该计划的成熟提供进一步的见解。”。

Abstract #5313: CB307: A dual targeting costimulatory Humabody® VH therapeutic for treating PSMA-positive tumours

摘要#5313:CB307：用于治疗PSMA阳性肿瘤的双靶向共刺激Humabody®VH治疗剂

The functional activity of CB307, a first-in-class CD137 x PSMA bispecific Humabody®, designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, was assessed in preclinical models.

在临床前模型中评估了CB307的功能活性，CB307是一流的CD137 x PSMA双特异性Humabody®，旨在实现更持久的抗癌作用，同时避免全身毒性。

The details of this research have also been published in Clinical Cancer Research, a journal of the AACR. The paper, ‘CB307: A dual targeting costimulatory Humabody® VH therapeutic for treating PSMA-positive tumours’, co-authored by Crescendo scientists and Regius Professor of Cancer Research, Johann de Bono from The Institute of Cancer Research, London, reports:.

这项研究的细节也发表在AACR杂志《临床癌症研究》上。这篇论文“CB307：一种用于治疗PSMA阳性肿瘤的双靶向共刺激Humabody®VH治疗剂”，由Crescendo科学家和伦敦癌症研究所的Regius癌症研究教授Johann de Bono合著，报道：。

CB307 demonstrated effective activation of both T and NK cells via the co-stimulatory receptor CD137 in a PSMA-dependent manner

CB307通过共刺激受体CD137以PSMA依赖性方式有效激活T细胞和NK细胞

Its combination with PD-(L)1 inhibitors showed supra-additive anti-tumour activity, which is retained even in absence of tumour PD-L1 expression, potentially enabling a wider patient population to benefit from checkpoint inhibitor therapies

它与PD-（L）1抑制剂的组合显示出超加性抗肿瘤活性，即使在没有肿瘤PD-L1表达的情况下也能保留这种活性，这可能使更广泛的患者群体受益于检查点抑制剂疗法

Although prostate cancer has been considered an ‘immunologically cold’ tumour type, the data revealed co-localisation of CD137 and PSMA in metastatic prostate cancer lesions, supporting the use of CB307 in mCRPC

尽管前列腺癌被认为是一种“免疫性感冒”肿瘤类型，但数据显示CD137和PSMA在转移性前列腺癌病变中共定位，支持在mCRPC中使用CB307

Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, comments: “The data shared at AACR and published in Clinical Cancer Research support this novel candidate’s (CB307) clinical evaluation in PSMA+ mCRPC, both as a monotherapy and in combination settings.”.

伦敦癌症研究所（Institute of Cancer Research，London）癌症研究Regius教授约翰·德博诺（Johann de Bono）教授评论道：“在AACR上共享并在临床癌症研究中发表的数据支持了这位新候选人（CB307）在PSMA+mCRPC中的临床评估，无论是作为单一疗法还是联合治疗。”。

Abstract #5302: CB699: A novel mesothelin-binding Humabody® CD40 and CD137 dual-agonist for enhancing immune cell responses against MSLN+ tumours

摘要#5302:CB699：一种新型间皮素结合Humabody®CD40和CD137双重激动剂，用于增强针对MSLN+肿瘤的免疫细胞反应

Derived from the Humabody® VH platform, CB699 is Crescendo’s first candidate in a novel class of tumour antigen-directed CD40 and CD137 dual agonists, designed to enhance the anti-tumour activity of multiple immune cell types. CB699 is a half-life extended CD40 x CD137 x MSLN trispecific molecule. The preclinical studies support Crescendo’s progression of the candidate towards clinical development:.

CB699源自Humabody®VH平台，是Crescendo在一类新型肿瘤抗原定向CD40和CD137双重激动剂中的第一个候选药物，旨在增强多种免疫细胞类型的抗肿瘤活性。CB699是半衰期延长的CD40 x CD137 x MSLN三特异性分子。临床前研究支持渐强的候选人向临床发展的进展：。

Pharmacokinetic data including preclinical dose range finding and half-life of CB699 support clinical development;

药代动力学数据（包括临床前剂量范围发现和CB699的半衰期）支持临床开发；

The results demonstrated CB699’s ability to conditionally enhance both T cell and antigen-presenting cell (APC) signalling axes, providing a comprehensive anti-cancer immune response; and

结果表明CB699能够有条件地增强T细胞和抗原呈递细胞（APC）信号轴，提供全面的抗癌免疫应答；和

The trispecific format was able to drive conditional CD40 agonism in the presence of either CD137+ or MSLN+ cells, and similarly, conditional CD137 agonism in the presence of either CD40+ or MSLN+ cells, potentially providing a potent yet safe way to target heterogeneous tumours

三特异性形式能够在CD137+或MSLN+细胞存在下驱动条件性CD40激动，类似地，在CD40+或MSLN+细胞存在下驱动条件性CD137激动，可能为靶向异质性肿瘤提供有效但安全的方法

Both abstracts are available on the AACR website and the posters are available on the Crescendo website under Posters & Publications.

这两篇摘要都可以在AACR网站上找到，海报可以在Crescendo网站的海报和出版物下找到。

About CB307

关于CB307

CB307 is Crescendo’s lead clinical candidate, a first-in-class, half-life extended, CD137 x PSMA bispecific Humabody®, designed to deliver a safer and more durable anti-cancer response.

CB307是Crescendo的首席临床候选人，是一流的延长半衰期的CD137 x PSMA双特异性Humabody®，旨在提供更安全，更持久的抗癌反应。

CB307 conditionally activates only tumour-specific T cells, exclusively within the tumour microenvironment, using the CD137 co-stimulatory mechanism. Its unique format enables potent, tumour-specific killing, while avoiding systemic toxicity and can be applied to a broad range of PSMA+ cancer indications to address a large unmet medical need..

CB307使用CD137共刺激机制仅在肿瘤微环境内有条件地激活肿瘤特异性T细胞。其独特的形式可以实现有效的肿瘤特异性杀伤，同时避免全身毒性，并可应用于广泛的PSMA+癌症适应症，以解决大量未满足的医疗需求。。

Clinical development of CB307 is on track with the Phase 1b POTENTIA trial ongoing in adult patients with PSMA+ metastatic castration-resistant prostate cancer (mCRPC). POTENTIA (NCT04839991) is an open-label, dose escalation and cohort expansion study to assess the safety, tolerability and preliminary efficacy of CB307 as a monotherapy and in combination with pembrolizumab (KEYTRUDA®)..

随着PSMA+转移性去势抵抗性前列腺癌（mCRPC）成年患者正在进行的1b期POTENTIA试验，CB307的临床开发正在进行中。POTENTIA（NCT04839991）是一项开放标签，剂量递增和队列扩展研究，用于评估CB307作为单一疗法和与pembrolizumab（KEYTRUDA®）联合使用的安全性，耐受性和初步疗效。。

About CB699

关于CB699

CB699, a half-life extended CD40 x CD137 x mesothelin (MSLN) trispecific molecule, is the second candidate in Crescendo’s proprietary pipeline of novel, targeted immune-cell-enhancing therapeutics, derived from its Humabody® VH platform. CB699 aims at enhancing immune cell activity against MSLN+ tumours, using both immune cell and APC signalling axes..

CB699是一种半衰期延长的CD40 x CD137 x间皮素（MSLN）三特异性分子，是Crescendo专有的新型靶向免疫细胞增强疗法管道中的第二个候选药物，源自其Humabody®VH平台。CB699旨在使用免疫细胞和APC信号轴增强针对MSLN+肿瘤的免疫细胞活性。。

About Crescendo Biologics

关于Crescendo Biologics

Crescendo Biologics is a private, clinical-stage immuno-oncology company developing novel, targeted immune cell-enhancing therapeutics derived from its proprietary Humabody® VH platform. Beyond Crescendo’s proprietary pipeline, the Company has global, multi-target discovery and development collaborations with Takeda and BioNTech, and an exclusive worldwide licensing agreement with Zai Lab.

Crescendo Biologics是一家私人临床阶段免疫肿瘤学公司，开发新型靶向免疫细胞增强疗法，该疗法源自其专有的Humabody®VH平台。除了Crescendo的专有渠道之外，该公司还与武田和BioNTech进行了全球多目标发现和开发合作，并与Zai Lab达成了全球独家许可协议。